Summary:
- Xueshan Zhang, a Harvard alumnus with an SM degree from 2014, is the co-founder and CEO of Nanopath, a biotechnology company developing a rapid, low-cost diagnostic platform for infectious diseases.
- Nanopath's technology uses nanomaterials to detect and identify pathogens, enabling faster and more accurate diagnosis compared to traditional methods.
- Zhang's work at Nanopath aims to improve global health by providing accessible and affordable diagnostic tools, particularly in underserved communities.